Diabetes-Cardiorenal-Metabolic Medicine
A four-hour postgraduate-level taster of the four-microcredential PGCert in DCRM. Anchored to DCRM 2.0 (Handelsman et al, 2024), the AHA Cardiovascular-Kidney-Metabolic syndrome framework, KDIGO 2024, the 2025 ESC/EAS dyslipidaemia focused update, NICE NG28/NG203/NG238, and the emerging UK pipeline.
~4 hours · 12 sections · 3 Tier-3 cases · 8 AKT SBAs · CPD certificate · Independent & non-promotional
mdacumen.com › Academy › Sample modules › PGCert in DCRM › Foundations Introduction · 4-hour PGCert taster
Personalise your CPD certificate
Enter the name you would like to appear on your certificate. The name is stored locally in your browser only and is never sent anywhere.
Reflective practice prompts are at the end. Spend five minutes on them — that is the part of CPD that changes behaviour.
The single largest preventable disease burden in primary care
Diabetes, atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), heart failure (HF), obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) are the dominant non-communicable contributors to UK morbidity, mortality and NHS spend. They cluster in the same person; they share pathophysiology; and they are now treatable as a single continuum rather than as separate organ-system problems.
What changed. The old “diabetologist treats glucose, cardiologist treats arteries, nephrologist treats kidneys” model has been formally dismantled by three convergent statements: DCRM 2.0 (Handelsman et al, 2024, 22 multispecialty recommendations); the AHA Cardiovascular-Kidney-Metabolic (CKM) Syndrome Presidential Advisory (Ndumele et al, 2023); and the 2025 ESC/EAS focused update on dyslipidaemia. All three call for one integrated treatment plan per patient — across glucose, lipids, blood pressure, kidney function, weight, and inflammation.
Learning objectives — by the end of this taster module you will be able to
The PGCert microcredential roadmap
This four-hour taster previews the foundation concepts of all four 15-credit microcredentials in the MD Acumen-NVU PGCert in DCRM. Each microcredential is a standalone FHEQ Level 7 / 7.5 ECTS qualification; together they earn the full 60-credit Postgraduate Certificate.
Cardiovascular Risk & Lipid Management
QRISK3 / SCORE2 / PREVENT in real life. ApoB and Lp(a) as “the new LDL”. Statin-first ladder; ezetimibe; bempedoic acid; alirocumab / evolocumab / inclisiran; the icosapent-ethyl niche. ESC/EAS 2025 LDL targets including the new extreme-risk <1.0 mmol/L floor.
Diabetes & Cardiometabolic Therapy
Modern T2DM ladder: metformin plus a cardiometabolic-benefit drug from the outset. Even-handed across the four UK-licensed SGLT2 inhibitors, five UK-licensed GLP-1 receptor agonists, tirzepatide, and the safe deprescribing of sulfonylureas. Sick-day rules, hypoglycaemia, technology.
Cardiorenal — CKD & Heart Failure
KDIGO 2024 heat map; albuminuria-first thinking; the kidney-heart axis. Quadruple therapy in HFrEF; finerenone in HFmrEF/HFpEF after FINEARTS-HF; SGLT2 inhibitors across the EF spectrum; FLOW data on semaglutide and CKD outcomes.
Obesity, MASLD & Inflammation
Obesity as a chronic disease (Lancet 2024 redefinition). Anti-obesity pharmacology: liraglutide, semaglutide, tirzepatide, and the next-generation triple agonist retatrutide. MASLD/MASH pathway with FIB-4 first; resmetirom; STEP-MASH semaglutide. Inflammation as the fifth pillar — colchicine, IL-6 / IL-1β.
One pathophysiology, many organ failures
The reason DCRM works as a single specialty is that the same handful of upstream mechanisms — insulin resistance, ectopic adiposity, low-grade inflammation, neurohormonal activation, endothelial dysfunction and lipid retention — produce all the downstream end-organ injury we see in primary care. Treat the upstream biology and the downstream syndromes converge.
Mind map — the DCRM continuum
The figure below shows how a single biological hub (cardiometabolic inflammation and insulin resistance) radiates into eight syndromic outputs. Note that every spoke is now therapeutically tractable with one or more agents that overlap across spokes — that is the structural reason DCRM medicine is a discipline.
Eight syndromic outputs; one upstream biology. Every modern DCRM drug class — SGLT2 inhibitors, GLP-1 receptor agonists, finerenone, statins / PCSK9 inhibitors, anti-inflammatories — touches more than one spoke.
Why this matters in clinic
If you take any patient with type 2 diabetes registered in your practice and look hard, you will find the other spokes in nearly every case. Median additional comorbidities per T2DM patient in UK primary care exceed three. The clinical question is therefore not which condition to treat first but which drugs cover the most spokes.
Pearl. SGLT2 inhibitors lower glucose, weight, blood pressure, albuminuria, eGFR slope, hospitalisation for heart failure, and progression to dialysis — across patients with and without diabetes. A single drug class covers six of the eight spokes. That is the modern definition of a DCRM drug.
DCRM 2.0 — the 22-recommendation framework at a glance
DCRM 2.0 was published in Metabolism in June 2024 by an international 60-author multispecialty task force led by Yehuda Handelsman. It expands DCRM 1.0 (2022) from a US to a global frame, adds two slides on emerging medications, and refines lipid goals. The 22 recommendations sit in four sections.
| Section | Recommendations | What is new in 2.0 |
|---|---|---|
| I — General health | Lifestyle therapy · Patient education · Technology & digital care · Clinical tests · Cognitive function · Vaccinations | Cognitive function added as a stand-alone recommendation. Technology and CGM widely endorsed for non-T1DM populations. |
| II — Cardiorenal risk | Obesity · Prediabetes · Lipid disorders · Hypertension · Inflammation · Antihyperglycaemic therapy · Hypoglycaemia · Antiplatelet / anticoagulation | Inflammation now its own recommendation, with hsCRP integrated into ASCVD risk; lipid goals harmonised with ApoB / non-HDL targets and an extreme-plus <1.04 mmol/L LDL-C floor. |
| III — Cardiorenal & metabolic comorbidities | Pulmonary disease · MASLD/MASH · ASCVD prevention & management · HF prevention & management · CKD prevention & management · Comorbid HF + CKD | Pulmonary disease (OSA, COPD interactions) added; MASLD pathway formalised with FIB-4 first; comorbid HF + CKD given its own slide. |
| IV — Implications for management | Summary of medications (two slides covering all DCRM drug classes) | Two slides instead of one — explicit even-handed coverage of UK-licensed and US-licensed agents. |
CKM syndrome staging — the AHA framework (Ndumele 2023)
The AHA Presidential Advisory on Cardiovascular-Kidney-Metabolic Syndrome introduced a staged construct that complements DCRM 2.0. It is the clearest framework for explaining to a patient — and to a CCG / ICB commissioner — why the same person needs cardiology, nephrology and endocrinology thinking applied at once.
| CKM Stage | Definition | Primary-care priorities |
|---|---|---|
| Stage 0 | No CKM risk factors | Maintain healthy weight, activity, diet, no tobacco; QRISK3 / PREVENT every 5 years. |
| Stage 1 | Excess / dysfunctional adiposity (BMI ≥25, waist above sex-specific cut-off, prediabetes screening if BMI ≥30 or risk factors) | Lifestyle therapy; consider GLP-1 RA if obesity-related complication; UACR every 2–3 y. |
| Stage 2 | Metabolic risk factors (T2DM, hypertension, hypertriglyceridaemia, MetS) or moderate-/high-risk CKD | Annual UACR + eGFR; integrated lipid + glucose + BP plan; SGLT2i if T2DM or CKD ≥G3 / UACR ≥3 mg/mmol. |
| Stage 3 | Subclinical CVD or CKD risk equivalents (CAC ≥100, very-high-risk CKD per KDIGO, predicted high CV risk by PREVENT) | Statin to LDL < 1.8 mmol/L; consider PCSK9i / inclisiran if not at target; finerenone if T2DM-CKD with UACR ≥3 mg/mmol. |
| Stage 4 | Clinical CVD plus CKM risk factors (4a no kidney failure; 4b kidney failure) | Maximal secondary-prevention pharmacology; consider colchicine if recurrent events; icosapent ethyl if TG ≥1.7 mmol/L on statin. |
Beyond QRISK3 — ApoB, Lp(a), CAC and the KDIGO heat map
MRCGP teaches QRISK3 as a primary-care risk tool and that is appropriate for first-pass triage. PGCert-level practice, however, requires explicit handling of ApoB (the actual atherogenic particle count), Lp(a) (the unmodifiable inherited risk factor), CAC (the imaging biomarker that resolves middle-risk patients), and the KDIGO heat map (which alone reclassifies a substantial proportion of QRISK-low patients into high-risk DCRM management).
The KDIGO 2024 heat map — the single most important diagram in DCRM
The 2024 KDIGO update sharpens the GFR / albuminuria heat map and re-emphasises that albuminuria carries equivalent prognostic weight to GFR. A patient with eGFR 80 mL/min/1.73 m² and UACR 50 mg/mmol is at higher cardiovascular risk than one with eGFR 50 and UACR 1.
| eGFR (mL/min/1.73 m²) | A1: UACR < 3 mg/mmol | A2: UACR 3–30 mg/mmol | A3: UACR > 30 mg/mmol |
|---|---|---|---|
| G1: ≥90 | Low risk (only if no CKD markers) | Moderately increased | High |
| G2: 60–89 | Low | Moderately increased | High |
| G3a: 45–59 | Moderately increased | High | Very high |
| G3b: 30–44 | High | Very high | Very high |
| G4: 15–29 | Very high | Very high | Very high |
| G5: <15 / dialysis | Very high | Very high | Very high |
Translational pearl. Most UK practices retain ACR results as a tick-box behind diabetes annual review. The KDIGO heat map is the single most powerful tool for reclassifying patients into high-risk groups eligible for SGLT2 inhibitors (NICE TA775 dapagliflozin, TA989 empagliflozin) and finerenone (TA877). Run the search: T2DM + UACR ≥3 mg/mmol + not on SGLT2i. The denominator will surprise you.
ApoB and non-HDL-C — the modern atherogenic particle measure
LDL-C measures cholesterol mass; ApoB measures particle number. In the presence of small-dense LDL (typical in T2DM, MASLD, and obesity), LDL-C systematically underestimates atherogenic burden. ApoB is the more accurate, the more reproducible, and the more recommended biomarker. The 2025 ESC/EAS focused update endorses ApoB as the preferred secondary marker once LDL-C is at goal, and DCRM 2.0 specifies risk-tiered ApoB targets.
| Risk category | LDL-C target (mmol/L) | ApoB target (g/L) · non-HDL-C target (mmol/L) |
|---|---|---|
| Low / moderate (no CKM, low PREVENT) | < 3.0 (≥50% reduction) | ApoB < 1.0 · non-HDL < 3.4 |
| High (T2DM without target-organ damage; familial hypercholesterolaemia without ASCVD) | < 1.8 (≥50% reduction) | ApoB < 0.9 · non-HDL < 2.6 |
| Very high (established ASCVD; T2DM with target-organ damage; KDIGO very-high-risk CKD) | < 1.4 (≥50% reduction) | ApoB < 0.8 · non-HDL < 2.2 |
| Extreme (recurrent events on therapy; polyvascular disease) | < 1.0 (≥50% reduction; ESC/EAS 2025 NEW floor) | ApoB < 0.65 · non-HDL < 1.7 |
| Extreme-plus (events despite achieved LDL < 1.4) | < 1.04 (DCRM 2.0) | ApoB < 0.6 · non-HDL < 1.4 |
Lp(a) — once in a lifetime, then act on it
Lp(a) is the strongest single inherited dyslipidaemia and the most prevalent. Roughly one in five UK adults has Lp(a) above the established risk threshold (≥125 nmol/L or ≥50 mg/dL). It is unmodifiable by lifestyle and statins barely touch it (sometimes raise it). Until the antisense and siRNA agents arrive, the clinical implication of an elevated Lp(a) is to push the LDL-C and ApoB targets harder on every other lever — and to consider it a reason to escalate above QRISK3-suggested intensity.
Once-in-a-lifetime testing. Both ESC/EAS 2025 and DCRM 2.0 recommend Lp(a) measurement at least once in adulthood. The result re-classifies risk categorically: an Lp(a) ≥ 250 nmol/L confers an ASCVD relative risk roughly equivalent to LDL-C 4 mmol/L untreated. Document Lp(a) in the patient’s record permanently — there is no need ever to repeat the test in routine practice. (Ballantyne et al, JACC 2024; NLA 2024 focused update.)
CAC — the tie-breaker in middle-risk patients
For patients with QRISK3 in the 7.5–20% range, the coronary artery calcium (CAC) score reclassifies a meaningful proportion. A CAC of 0 in an asymptomatic patient over 50 is a “power of zero” signal — the 10-year ASCVD event rate is <1.5% and statin therapy may be safely deferred. A CAC ≥ 100 is a high-risk equivalent regardless of QRISK3. UK access remains patchy and largely private; emerging NHS adoption is via the JBS3 / Lifespan Lipid Pathway recommendations.
Risk-calculator comparison
| Calculator | Population & jurisdiction | Inputs & signature features |
|---|---|---|
| QRISK3 | UK primary care; NICE NG238 | 10-year fatal/non-fatal CVD; includes CKD, RA, mental illness, atypical antipsychotics, ED, SLE; ethnicity-stratified. |
| SCORE2 / SCORE2-OP | European, ESC 2021 | Region-stratified; fatal + non-fatal CVD; explicit older-person variant; not validated for diabetes (use SCORE2-Diabetes). |
| PREVENT | USA, AHA 2024 | 10-year & 30-year total CVD; includes eGFR, UACR, BMI, social determinants; integrates the CKM staging system. |
| ASSIGN | Scottish primary care | SIGN-recommended; deprivation index integrated. |
PGCert-level pearl. The PREVENT equations explicitly treat CKM as a continuum and incorporate eGFR and UACR into the risk score. They are the first risk calculator that models the cardiovascular price of CKD at primary-care presentation. Expect NICE to incorporate equivalent CKM-aware risk calculation in the next NG238 review cycle.
KDIGO 2024 heat map — eGFR × UACR risk grid
The KDIGO 2024 heat map remains the canonical primary-care instrument for CKD-risk stratification — and is the entry point for SGLT2 inhibitor (NICE TA775 / TA989) and finerenone (NICE TA877) eligibility. Read the grid as eGFR category × UACR category; the cell colour and label define the risk band.
| eGFR (mL/min/1.73 m²) | A1 · UACR < 3 mg/mmol | A2 · UACR 3–30 mg/mmol | A3 · UACR > 30 mg/mmol |
|---|---|---|---|
| G1 · ≥ 90 (normal) | Low risk | Moderately increased | High risk |
| G2 · 60–89 (mildly decreased) | Low risk | Moderately increased | High risk |
| G3a · 45–59 (mildly–moderately decreased) | Moderately increased | High risk | Very high risk |
| G3b · 30–44 (moderately–severely decreased) | High risk | Very high risk | Very high risk |
| G4 · 15–29 (severely decreased) | Very high risk | Very high risk | Very high risk |
| G5 · < 15 (kidney failure) | Very high risk | Very high risk | Very high risk |
Risk-band labels (Low / Moderately increased / High / Very high) align with KDIGO 2024 colour bands (green / yellow / orange / red). The MD Acumen DCRM PGCert teaches the heat map alongside the action triggers — SGLT2 inhibitor at eGFR ≥ 20 with UACR ≥ 22.6 mg/mmol (NICE TA775 / TA989); finerenone at eGFR > 25, UACR ≥ 3 mg/mmol, K⁺ ≤ 4.8 in T2DM-CKD (NICE TA877).
The drug-class-specific safety repertoire every DCRM prescriber must hold
The cardiometabolic toolkit has expanded faster than the safety teaching has spread. Each new class introduces a small but distinctive set of clinically important red flags. The list below is not exhaustive but covers the events most commonly seen in DCRM clinic referrals or UK MHRA Yellow Card reports over the last 24 months.
Euglycaemic DKA on SGLT2 inhibitors
Plasma glucose may be <14 mmol/L despite ketoacidosis. Triggers include insulin reduction, low-carbohydrate diet, alcohol, surgery, sepsis, prolonged fasting. Sick-day rule: stop SGLT2i during acute illness, dehydration, planned surgery, and recommence only when eating and drinking normally. MHRA DSU October 2020 reiterated. Test capillary ketones if the patient feels unwell, regardless of glucose level.
GLP-1 RA pancreatitis & gallstones
Symptomatic gallstones are class-effect (rate ~1.5×). Acute pancreatitis is rare but reported. Stop and reassess if persistent severe abdominal pain, especially radiating to back. New abdominal pain in a patient on liraglutide / dulaglutide / exenatide / semaglutide / tirzepatide is not normal and warrants amylase / lipase plus imaging. Do not re-challenge after biopsy-proven pancreatitis.
Hyperkalaemia under finerenone / ACEi / ARB / SGLT2i
Finerenone (a non-steroidal MRA, NICE TA877 in T2DM-CKD) elevates K+ less than spironolactone but still requires baseline K+ < 4.8 mmol/L and four-weekly K+ for the first three months, then quarterly. Combined RAAS blockade plus SGLT2i may unmask hyperkalaemia in CKD G3b/G4. Use chlorthalidone or indapamide (kaliuretic) preferentially over potassium-sparing combinations.
Acute kidney injury under combined RAAS-SGLT2i
An expected eGFR drop of up to 30% in the first 2–4 weeks of an SGLT2 inhibitor is haemodynamic, not toxic, and reverses on cessation. Do not stop unless drop is >30%, symptomatic, or accompanied by hyperkalaemia. Sick-day rule: withhold SGLT2i and ACEi/ARB during gastroenteritis, sepsis, or peri-operatively; restart once euvolaemic.
Hypoglycaemia under sulfonylurea + GLP-1 RA / insulin
Dose-reduce sulfonylurea by 50% when adding a GLP-1 RA; reassess at four weeks. The same applies to background insulin: pre-emptively reduce basal insulin by 20% on initiation of semaglutide or tirzepatide in T2DM if HbA1c < 64 mmol/mol. DCRM 2.0 reframes hypoglycaemia by Levels 1–3, with Level 3 (severe, requires assistance) as a never-event in modern T2DM management.
Lactic acidosis under metformin
Rare but devastating. Risk rises with eGFR < 30 mL/min/1.73 m², acute illness, contrast imaging in unwell inpatients, and severe liver disease. Withhold metformin if eGFR < 30; halve dose if 30–44; pause around iodinated contrast if eGFR ≤ 30 or AKI; review in 48 hours. NICE NG28 endorses the metformin sick-day rule alongside SGLT2i.
The DCRM sick-day mnemonic — SADMANS.
Withhold all of these during dehydrating illness; reinstate when eating, drinking, and urinating normally for 24 hours. Patient-facing wallet cards exist via Diabetes UK and the British Renal Society. Embed in your practice template.
From statin-first thinking to ApoB-target combination therapy
Lipid management is the single most evidence-rich domain in DCRM medicine. The 2025 ESC/EAS focused update, NICE NG238 (2023), DCRM 2.0 (2024), and the 2026 ACC/AHA/multisociety dyslipidaemia guideline all converge on the same lower-is-better principle, but with progressively more aggressive targets and progressively more combination therapy at first prescription. This section synthesises the foundational concepts that all four guidelines now share — and the disagreements that remain.
The lipid-lowering ladder — modern UK practice
The historic stepwise ladder (statin → up-titrate → maybe ezetimibe at 6 months → maybe PCSK9i at 12 months if NICE TA303 / TA394 met) is being replaced by combination from the outset when the LDL-C gap to target exceeds 50%. DCRM 2.0 explicitly recommends initial dual therapy in this circumstance.
High-intensity statin at the maximal tolerated dose
Atorvastatin 80 mg or rosuvastatin 20–40 mg are the UK first-line agents in secondary prevention. NICE NG238 endorses high-intensity (≥40% LDL-C reduction) for all primary-prevention QRISK3 ≥10% and for all secondary prevention. Check baseline LFTs and CK; recheck non-fasting lipid profile at 3 months. Re-test ALT and CK only if symptoms.
Ezetimibe 10 mg added if LDL-C above target
Adds a further ~18–22% LDL-C reduction. Generic, well tolerated, no renal dose adjustment. NICE NG238 recommends adding routinely if LDL-C remains > 1.4 mmol/L (very-high risk) or > 1.8 mmol/L (high risk) on max-tolerated statin. Combination atorvastatin/ezetimibe and rosuvastatin/ezetimibe single-pill products are now NHS-available.
Bempedoic acid (NICE TA694) — for statin intolerance or further LDL gap
An ATP-citrate lyase inhibitor active only in liver, not muscle. CLEAR Outcomes (Nissen, NEJM 2023) demonstrated 13% relative risk reduction in MACE in 13,970 statin-intolerant patients (HR 0.87, 95% CI 0.79–0.96; 21% LDL-C reduction). UK-licensed monotherapy or with ezetimibe (Nustendi). Useful in the genuine statin-intolerant; also available as an additive in patients on max-tolerated statin + ezetimibe still above target.
PCSK9 inhibition — alirocumab, evolocumab (mAbs) or inclisiran (siRNA)
Adds a further ~50–60% LDL-C reduction beyond statin + ezetimibe. UK-licensed pathway: NICE TA393/394 (alirocumab/evolocumab) and TA733 (inclisiran). Inclisiran is twice-yearly subcutaneous injection — high-volume potential in primary care once commissioning catches up. ORION-4 long-term outcome trial reads out 2026/27. Reserve PCSK9 mAbs for primary FH and secondary prevention with persistent LDL-C above target.
Adjunctive therapy — icosapent ethyl in residual hypertriglyceridaemia
If TG ≥ 1.7 mmol/L on max-tolerated statin AND established ASCVD with LDL 1.04–2.6 mmol/L, NICE TA805 recommends icosapent ethyl 2 g twice daily as add-on. REDUCE-IT showed 25% relative risk reduction in MACE. The mineral-oil-placebo controversy is acknowledged; the totality of evidence still favours use in the licensed sub-group.
Even-handed UK-licensed lipid-lowering pharmacology
| Agent | Class · target | UK route · NICE position |
|---|---|---|
| Atorvastatin | HMG-CoA reductase inhibitor | Oral; first-line per NICE NG238 for primary & secondary prevention. |
| Rosuvastatin | HMG-CoA reductase inhibitor | Oral; alternative first-line; greater LDL reduction at high doses; no clinically meaningful CYP3A4 issues. |
| Simvastatin · pravastatin · fluvastatin · pitavastatin | HMG-CoA reductase inhibitors | Oral; second-line where atorva or rosuva not tolerated; pitavastatin notable for minimal drug-interaction profile. |
| Ezetimibe | NPC1L1 cholesterol-absorption inhibitor | Oral; NICE TA385 supports add-on; widely used as combination first-line where LDL gap large. |
| Bempedoic acid (Nilemdo) · Bempedoic acid + ezetimibe (Nustendi) | ATP-citrate lyase inhibitor | Oral; NICE TA694 — statin-intolerant or above target on max-tolerated statin + ezetimibe. |
| Alirocumab | PCSK9 monoclonal antibody | SC every 2–4 weeks; NICE TA393 — primary FH and secondary prevention. |
| Evolocumab | PCSK9 monoclonal antibody | SC every 2–4 weeks; NICE TA394 — primary FH and secondary prevention. |
| Inclisiran | Hepatocyte-targeted siRNA against PCSK9 mRNA | SC twice yearly after loading; NICE TA733 — secondary prevention with persistent LDL ≥ 2.6 mmol/L. |
| Icosapent ethyl (Vazkepa) | Highly purified EPA omega-3 | Oral; NICE TA805 — secondary prevention with TG ≥ 1.7 mmol/L on statin. |
| Evinacumab | ANGPTL3 monoclonal antibody | IV; specialist; NICE TA889 — homozygous FH only. |
| Lomitapide | MTP inhibitor | Oral; specialist; homozygous FH; hepatotoxicity monitoring. |
| Fenofibrate · ciprofibrate · bezafibrate | PPAR-α agonists | Oral; specialist or primary care for severe hypertriglyceridaemia (TG > 5.7 mmol/L) to reduce pancreatitis risk; no MACE benefit. |
Translational pearl — the 50% rule. If a patient’s baseline LDL-C is more than 50% above target, DCRM 2.0 explicitly recommends starting dual therapy from the outset (statin + ezetimibe or statin + bempedoic acid) rather than the historic stepwise approach. The clinical reality: a patient at very-high risk with LDL-C 4.2 mmol/L (target < 1.4) needs to drop ≥ 67%, which a statin alone will not achieve.
Lipoprotein(a) — the inherited risk we cannot yet drug, but can act on
Approximately 20% of UK adults carry an Lp(a) ≥ 125 nmol/L (~50 mg/dL), the established risk threshold. The 2024 Ballantyne et al JACC pooled multi-ethnic cohort (n = 27,756; mean follow-up 21 years) confirmed that Lp(a) at the 90th percentile or above carries an adjusted hazard ratio of 1.46 for ASCVD events independent of LDL-C. The 2025 ESC/EAS focused update places an entire chapter on Lp(a). The 2024 NLA focused statement endorses once-in-a-lifetime measurement.
The PGCert framing. Until pelacarsen, olpasiran, lepodisiran or muvalaplin become available (covered in Section 10), elevated Lp(a) is managed by lowering everything else. Push the LDL target one risk-tier lower; treat blood pressure to < 130/80; consider low-dose colchicine if recurrent events; intensify lifestyle. The Heart UK consensus position recommends documenting Lp(a) once and treating accordingly.
Statin intolerance — the N-of-1 framework
True statin intolerance is far less common than reported in clinic — the SAMSON N-of-1 trial demonstrated that 90% of statin-intolerant symptoms recur on placebo. The pragmatic UK approach (Heart UK, BHF) is: (a) confirm symptoms with three different statins at three different doses; (b) consider hydrophilic statins (rosuvastatin, pravastatin); (c) try alternate-day dosing; (d) reframe with the patient before declaring intolerance; (e) once true intolerance established, use bempedoic acid + ezetimibe + PCSK9i / inclisiran as the alternative ladder.
Embedded knowledge check — Lipid pillar
Mini-SBA · 67-year-old man post-MI on atorvastatin 80 mg, latest LDL-C 2.1 mmol/L
A 67-year-old man with a non-ST-elevation myocardial infarction six months ago is reviewed in the post-MI clinic. He is on atorvastatin 80 mg, aspirin 75 mg, ticagrelor 90 mg twice daily, ramipril 10 mg, bisoprolol 5 mg, and dapagliflozin 10 mg. He has type 2 diabetes (HbA1c 52 mmol/mol), eGFR 64 mL/min/1.73 m², BP 128/76. Latest non-fasting lipid profile: total cholesterol 4.0, HDL-C 1.0, LDL-C 2.1, triglycerides 2.0 mmol/L. His Lp(a) was 32 nmol/L. He tolerates the statin without symptoms. What is the next step in lipid management?
Correct answer: B. NICE NG238 (2023) sets a secondary-prevention LDL-C target of < 2.0 mmol/L (or non-HDL-C < 2.6 mmol/L); ESC/EAS 2025 sets the very-high-risk LDL-C target at < 1.4 mmol/L; DCRM 2.0 endorses the very-high-risk threshold for an established ASCVD event with diabetes. He is above target by either yardstick. Adding ezetimibe gives a further ~20% LDL-C reduction with negligible toxicity, no renal adjustment, and is the consensus next step on max-tolerated statin (DCRM 2.0; NICE NG238). Switching statins (C) is unhelpful when atorva 80 is tolerated. Inclisiran (D) and PCSK9 mAbs (E) are appropriate after ezetimibe is in place and the LDL-C remains ≥ 2.6 mmol/L (NICE TA733/393/394). Lp(a) is < 75 nmol/L so does not push intensity higher.
From glucocentric to organocentric — the post-2023 consensus
The defining shift in modern T2DM care, codified in the ADA-EASD 2022 consensus, the ESC/EASD 2023 guideline, NICE NG28 (Aug 2022 update), DCRM 2.0 (2024), and the 2026 ACC/AHA dyslipidaemia guideline, is that drug choice now follows organ protection rather than glucose lowering. For a person with established ASCVD, CKD, or HF, an SGLT2 inhibitor or a GLP-1 receptor agonist is indicated regardless of baseline HbA1c — and metformin is no longer obligatory as a precursor.
The modern T2DM ladder
Stratify by indication, not by HbA1c
Three questions at diagnosis: (a) does the patient have established ASCVD or high CV risk? (b) does the patient have HF (preserved or reduced EF)? (c) does the patient have CKD (eGFR < 60 or UACR ≥ 3 mg/mmol)? A “yes” to any of these triggers an organ-protective agent first, irrespective of HbA1c.
SGLT2 inhibitor — the cardiorenal anchor
NICE NG28 endorses dapagliflozin / empagliflozin / canagliflozin / ertugliflozin in T2DM with established CVD or high CV risk. Cardiorenal benefits are independent of glucose effect: HF hospitalisation reduction in EMPEROR / DAPA-HF; CKD progression reduction in DAPA-CKD / EMPA-KIDNEY. Withhold during sick days (SADMANS).
GLP-1 receptor agonist — for ASCVD and weight
Liraglutide, dulaglutide, exenatide, lixisenatide, semaglutide (oral or SC) all UK-licensed in T2DM. SUSTAIN-6 and LEADER demonstrated MACE reduction in established CVD; FLOW (semaglutide 1 mg, NEJM 2024) showed kidney composite outcome reduction in T2DM-CKD. Combined GLP-1 + SGLT2i is now a routine pairing for T2DM with multimorbidity.
Tirzepatide — dual GIP/GLP-1 agonist
NICE TA924 (T2DM, Sept 2023) and TA1026 (obesity, May 2024) recommend tirzepatide. SURPASS-CVOT (2025) demonstrated non-inferiority to dulaglutide on 3-point MACE with superior glycaemic and weight outcomes. Sweet spot in T2DM with BMI ≥ 30 where greater HbA1c and weight reduction is required.
Metformin — still first-line for HbA1c lowering without CV/CKD/HF indication
NICE NG28 retains metformin as first-line where there is no organ-protective indication. Standard release titrated to 2 g/day; switch to MR if GI intolerance. Avoid if eGFR < 30; halve dose at 30–44. Pioglitazone is an option in insulin resistance and for stroke secondary prevention (PROactive, IRIS) but contraindicated in HF.
Sulfonylureas — deprescribe where possible
Hypoglycaemia risk and weight gain make gliclazide/glimepiride a poor fit for the modern DCRM patient. Where retained, halve dose on adding GLP-1 RA. DCRM 2.0 explicitly demotes them; consider deprescribing rather than escalation in any frail patient or any patient with CKD ≥ G3.
Even-handed UK-licensed cardiometabolic pharmacology
| Agent | Class · key trial · indication | UK position |
|---|---|---|
| Dapagliflozin | SGLT2i · DAPA-HF, DAPA-CKD, DECLARE-TIMI 58 | NICE NG28 (T2DM); TA679 (HFrEF); TA902 (HFmrEF/HFpEF); TA775 (CKD). |
| Empagliflozin | SGLT2i · EMPEROR-Reduced/Preserved, EMPA-KIDNEY, EMPA-REG OUTCOME | NICE NG28; TA773 (HFrEF); TA929 (HFmrEF/HFpEF); TA989 (CKD). |
| Canagliflozin | SGLT2i · CANVAS, CREDENCE | NICE NG28; CKD evidence in T2DM albuminuria. |
| Ertugliflozin | SGLT2i · VERTIS-CV (neutral) | NICE NG28 retains as option; less compelling cardiorenal evidence. |
| Liraglutide | GLP-1 RA daily SC · LEADER, SCALE | NICE NG28 (T2DM); TA664 (obesity adolescent/adult); off-label use in obesity at 3 mg. |
| Dulaglutide | GLP-1 RA weekly SC · REWIND, AWARD | NICE NG28; broad CV outcome benefit; primary & secondary prevention. |
| Exenatide | GLP-1 RA · EXSCEL (neutral primary CV) | NICE NG28 retains as option. |
| Lixisenatide | GLP-1 RA · ELIXA (neutral) | NICE NG28 retains as option. |
| Semaglutide (SC weekly · oral daily) | GLP-1 RA · SUSTAIN-6, STEP, SELECT, FLOW, STEP-HFpEF | NICE NG28; TA875 (obesity SC); STEP-HFpEF and FLOW have driven a step-change in HF and CKD evidence. |
| Tirzepatide | Dual GIP/GLP-1 · SURPASS, SURMOUNT, SURPASS-CVOT | NICE TA924 (T2DM); TA1026 (obesity). |
| Finerenone | Non-steroidal MRA · FIDELIO-DKD, FIGARO-DKD, FINEARTS-HF | NICE TA877 (T2DM with CKD UACR ≥ 3 mg/mmol); FINEARTS-HF data drives anticipated NICE expansion to HFmrEF/HFpEF. |
| Metformin | Biguanide · UKPDS | NICE NG28 first-line if no organ-protective indication. |
| Pioglitazone | PPAR-γ agonist · PROactive, IRIS, TOSCA-IT | NICE NG28 retained option; useful in insulin resistance and stroke secondary prevention; contraindicated in HF. |
| DPP-4 inhibitors (sitagliptin / linagliptin / saxagliptin / alogliptin / vildagliptin) | · TECOS, CARMELINA, SAVOR-TIMI | NICE NG28 retains; saxagliptin caution in HF; useful where eGFR low (linagliptin no renal adjustment). |
Translational pearl — the 4-pillar prescription. The contemporary DCRM patient with T2DM + ASCVD + CKD + HFpEF is on metformin, an SGLT2 inhibitor, a GLP-1 receptor agonist or tirzepatide, a high-intensity statin (with or without ezetimibe / PCSK9i / inclisiran), an ACE inhibitor or ARB, a beta-blocker if HF, and finerenone if T2DM-CKD with albuminuria. That is eight agents — but each is in there to cover a defined spoke. Polypharmacy reviewed against a four-pillar checklist looks rational, not excessive.
Glycaemic targets in DCRM 2.0 framework
| Population | HbA1c target | Notes |
|---|---|---|
| Most adults with T2DM | ≤ 53 mmol/mol (7.0%) | NICE NG28; ADA 2026; achievable with low risk of hypoglycaemia using SGLT2i / GLP-1 RA / metformin combinations. |
| Younger newly-diagnosed adults without CV/CKD/HF | ≤ 48 mmol/mol (6.5%) | NICE NG28 individualised target; legacy benefit (UKPDS). |
| Established ASCVD, hypoglycaemia history, advanced CKD, frailty, limited life expectancy | ≤ 64 mmol/mol (8.0%) | NICE NG28; DCRM 2.0; avoid lower targets where risk-benefit unfavourable. |
| Pregnancy / preconception (T2DM) | ≤ 48 mmol/mol if achievable safely | NICE NG3; switch to insulin or metformin; stop SGLT2i and GLP-1 RA pre-conception. |
Embedded knowledge check — Diabetes pillar
Mini-SBA · 58-year-old man with newly diagnosed T2DM and previous NSTEMI
A 58-year-old taxi driver attends for review eight weeks after his annual blood test showed HbA1c 64 mmol/mol. He has a history of an NSTEMI 18 months ago, treated with a drug-eluting stent and is on aspirin, ticagrelor, atorvastatin 80 mg, ramipril 10 mg and bisoprolol 5 mg. BMI 31 kg/m², BP 134/82, eGFR 78, UACR 1.8 mg/mmol. He is asymptomatic and would prefer not to have an additional injection. What first-line glucose-lowering therapy aligns with NICE NG28 (2022 update) and DCRM 2.0?
Correct answer: C. NICE NG28 (Aug 2022 update) explicitly recommends an SGLT2 inhibitor with proven cardiovascular benefit at first-line for any adult with T2DM and established ASCVD, regardless of baseline HbA1c — alongside or in place of metformin. DCRM 2.0 endorses the same logic. EMPA-REG OUTCOME demonstrated 14% MACE reduction and 38% CV-mortality reduction in T2DM with established CVD; DAPA-HF and EMPEROR-Reduced extend the benefit irrespective of diabetes status. Metformin (A) is no longer the obligatory first agent in this scenario. Sulfonylureas (B) introduce hypoglycaemia and weight gain. DPP-4 inhibitors (D) are CV-neutral. Insulin (E) is reserved for failure of oral plus injectable non-insulin therapies (NICE NG28).
The kidney-heart axis is one disease — manage it as one
CKD and HF share the same neurohormonal pathophysiology — RAAS activation, sympathetic excess, fibrosis, and shared response to SGLT2 inhibition and to mineralocorticoid receptor antagonism. KDIGO 2024, the 2023 ESC HF focused update, FINEARTS-HF (2024), DELIVER (2022), EMPA-KIDNEY (2023) and FLOW (2024) have collectively unified the cardiorenal therapeutic playbook.
KDIGO 2024 — what changed
Five practice-changing points from KDIGO 2024.
HFrEF — the four-pillar quadruple therapy
HFrEF (LVEF ≤ 40%) management has consolidated into a four-pillar regimen, started rapidly together rather than sequentially. The 2023 ESC focused update endorses initiating all four within 4–6 weeks of diagnosis where tolerated.
Pillar 1 · ARNI (or ACEi / ARB)
Sacubitril-valsartan (Entresto) preferred per NICE TA388. Start at 24/26 mg twice daily; titrate to 97/103 mg twice daily over 4–6 weeks. Switch from ACEi with 36-hour washout to avoid angioedema.
Pillar 2 · Beta-blocker (HF-licensed)
Bisoprolol, carvedilol, or nebivolol. Titrate slowly only when euvolaemic. Continue lifelong unless overt cardiogenic shock. Mortality benefit independent of EF in HFrEF.
Pillar 3 · MRA
Spironolactone 25–50 mg or eplerenone 25–50 mg in HFrEF (RALES, EMPHASIS-HF). Switch to non-steroidal MRA finerenone in HFmrEF/HFpEF post-FINEARTS-HF.
Pillar 4 · SGLT2 inhibitor
Dapagliflozin (NICE TA679, HFrEF; TA902, HFmrEF/HFpEF) or empagliflozin (TA773, HFrEF; TA929, HFmrEF/HFpEF). 26% relative reduction in CV death or HF hospitalisation across the EF spectrum.
HFmrEF / HFpEF — the post-FINEARTS-HF era
For LVEF > 40%, the regimen is anchored on (a) an SGLT2 inhibitor (DELIVER, EMPEROR-Preserved); (b) finerenone for HFmrEF/HFpEF (FINEARTS-HF, NEJM 2024 — 16% relative reduction in total worsening HF events plus CV death, n=6,001); (c) loop diuretic for symptomatic congestion; (d) treatment of co-existing AF, hypertension, MASLD, OSA. ARNI, ACEi/ARB and beta-blocker indications are weaker but reasonable where co-existing hypertension, CAD or AF rate-control demand them.
Pearl — FINEARTS-HF. Finerenone became the first MRA to demonstrate benefit in HFmrEF/HFpEF after the negative spironolactone TOPCAT trial. The hazard ratio for the primary composite of total worsening HF events plus CV death was 0.84 (95% CI 0.74–0.95). Anticipated UK NICE expansion of TA877 to HFmrEF/HFpEF is the most-watched cardiorenal regulatory event of 2026.
FLOW — semaglutide in CKD
The 2024 FLOW trial (semaglutide 1 mg subcutaneous weekly, n=3,533, T2DM with eGFR 25–75 and UACR 30–5,000 mg/g) demonstrated a 24% relative reduction in the kidney composite (sustained ≥ 50% eGFR decline, kidney failure, kidney-cause death, CV death). It is the first GLP-1 RA to deliver hard renal outcome benefit and reframes the GLP-1 RA + SGLT2i combination as the cardiorenal cornerstone in T2DM-CKD with albuminuria.
Embedded knowledge check — Cardiorenal pillar
Mini-SBA · 71-year-old woman with HFpEF and T2DM
A 71-year-old woman with T2DM (HbA1c 56 mmol/mol on metformin and dapagliflozin) attends with progressive exertional dyspnoea over six months. Echocardiogram shows LVEF 56%, grade II diastolic dysfunction, raised E/e′ ratio. NT-proBNP 920 ng/L. eGFR 52 mL/min/1.73 m², UACR 8 mg/mmol, K⁺ 4.4 mmol/L, BP 132/76. She is on ramipril 10 mg, indapamide 2.5 mg, atorvastatin 40 mg. She has no history of hyperkalaemia. What is the most appropriate next pharmacological step?
Correct answer: D. She has HFpEF (LVEF ≥ 50%, raised NT-proBNP, diastolic dysfunction) with T2DM-CKD (eGFR < 60 and UACR ≥ 3 mg/mmol). FINEARTS-HF (Solomon, NEJM 2024; n=6,001; HR 0.84) established finerenone as the first MRA with HFmrEF/HFpEF benefit. KDIGO 2024 endorses finerenone in T2DM-CKD with UACR ≥ 3 mg/mmol once K⁺ ≤ 4.8 mmol/L on max-tolerated ACEi/ARB — both criteria met. She is already on an SGLT2 inhibitor. Spironolactone (C) was negative in the parent TOPCAT trial; the post-Americas analysis is hypothesis-generating only. Sacubitril-valsartan (B) showed neutral primary outcome in PARAGON-HF in the HFpEF population. Beta-blocker (A) is appropriate for HFrEF, AF or angina but does not have HFpEF mortality benefit. Imaging (E) does not address pharmacology gap.
Obesity is a chronic disease, MASLD is the liver expression of that disease, and inflammation is the unifier
The 2024 Lancet Diabetes & Endocrinology Commission redefined obesity as a chronic disease with two phenotypes: pre-clinical (BMI ≥ 30 without organ-system harm) and clinical (with measurable end-organ harm). NICE NG246 (2026 update) and the AACE 2024 obesity algorithm follow. MASLD now affects ~30% of UK adults and ~70% of those with T2DM; FIB-4 is the first-line non-invasive screen. Inflammation is the through-line that links the two — and gives us colchicine, IL-6, IL-1β as a fifth therapeutic pillar.
Anti-obesity pharmacology — UK-licensed agents
| Agent | Class · key trial · weight loss | UK position |
|---|---|---|
| Orlistat | Lipase inhibitor · XENDOS · ~3% additional weight loss | NICE CG189 retained as low-cost option; modest efficacy. |
| Liraglutide 3 mg (Saxenda) | GLP-1 RA daily SC · SCALE · ~6% weight loss | NICE TA664 (adolescents and adults). |
| Semaglutide 2.4 mg (Wegovy) | GLP-1 RA weekly SC · STEP-1/4 · ~15% weight loss; SELECT — 20% MACE reduction | NICE TA875 — specialist weight-management services with two-year stop-rule; primary care prescribing under shared care arrangements. |
| Tirzepatide 5–15 mg (Mounjaro) | Dual GIP/GLP-1 weekly SC · SURMOUNT-1 · ~21% weight loss; SURMOUNT-2 in T2DM | NICE TA1026 (obesity) — phased NHS rollout 2024–2027. |
| Naltrexone-bupropion (Mysimba) | Combination · COR-I/II · ~5% weight loss | Available privately; not NICE-positive for routine NHS use. |
| Setmelanotide | MC4R agonist · for genetic obesity (POMC, LEPR, PCSK1) | NICE TA901 — specialist genetic obesity only. |
Pearl — the SELECT trial. SELECT (semaglutide 2.4 mg, Lincoff, NEJM 2023, n=17,604) demonstrated 20% MACE reduction in adults with obesity and established CVD without diabetes. This is the trial that re-classified anti-obesity pharmacology as cardiovascular pharmacology. NICE response is incorporated into TA875 and the 2025 ESC/EAS focused update.
MASLD — the new primary-care pathway
MASLD (formerly NAFLD) is diagnosed by hepatic steatosis (imaging or histology) plus at least one cardiometabolic risk factor. MASH is the inflammatory subset with hepatocyte ballooning and fibrosis. Approximately 30% of UK adults; 70% of those with T2DM; 50% of those with obesity. The clinical importance is liver fibrosis stage — F2+ portends liver-related and cardiovascular outcomes.
Identify the at-risk patient
Trigger MASLD screen: T2DM, BMI ≥ 30, metabolic syndrome, persistent ALT > ULN, abnormal imaging incidentally noting fatty liver. Check ALT, AST, GGT, platelets, full lipid profile, HbA1c, ferritin, autoantibodies if < 50 years, alcohol history.
FIB-4 calculator — the universal first non-invasive test
FIB-4 = (Age × AST) / (Platelets × √ALT). Cut-offs: < 1.30 low risk (no further work-up; recheck 2–3-yearly); 1.30–2.67 indeterminate (proceed to elastography or ELF); > 2.67 high risk (refer to hepatology).
Second-line non-invasive — transient elastography (FibroScan) or ELF
FibroScan LSM < 8 kPa low risk; 8–15 kPa indeterminate; > 15 kPa likely advanced fibrosis. Enhanced Liver Fibrosis (ELF) score < 9.8 low; ≥ 9.8 high. NICE NG49 and BSG/EASL pathways converge on FIB-4 → FibroScan.
Treat the cardiometabolic root cause
Weight loss ≥ 7–10% reverses MASH histology in ~50%. GLP-1 RAs and tirzepatide reduce hepatic fat fraction (STEP, SURPASS sub-studies). Semaglutide 2.4 mg STEP-MASH (NEJM 2024) showed MASH resolution without fibrosis worsening at 72 weeks.
Resmetirom — first MASH-licensed agent (US 2024)
Thyroid hormone receptor-β agonist; FDA-approved 2024 for MASH with F2-F3 fibrosis (MAESTRO-NASH); EMA/NICE submission ongoing 2025–26. Anticipated UK arrival via specialist hepatology.
Inflammation — the fifth pillar
Inflammation contributes to ASCVD risk independently of LDL-C. CANTOS (canakinumab, anti-IL-1β; Ridker, NEJM 2017) was the first to prove the inflammatory hypothesis of atherosclerosis. LoDoCo2 (low-dose colchicine 0.5 mg, Nidorf, NEJM 2020) and COLCOT (Tardif, NEJM 2019) translated this into a usable oral agent: relative reduction in MACE of ~31% in stable CAD with persistent residual inflammatory risk. FDA approved 2023; NICE evaluation pending. DCRM 2.0 endorses low-dose colchicine for residual inflammatory risk after maximal lipid lowering.
Practical hsCRP thinking. Measure hsCRP at the same time as the lipid profile in patients with established ASCVD or T2DM and intermediate / high CV risk. Persistent hsCRP ≥ 2 mg/L on a maximally-tolerated statin defines “residual inflammatory risk” — the population that benefits most from low-dose colchicine and where IL-6 / IL-1β biological pathways are an active future target (covered in Section 10).
Embedded knowledge check — Obesity / MASLD pillar
Mini-SBA · 46-year-old woman with prediabetes and incidental fatty liver
A 46-year-old woman is reviewed after an abdominal ultrasound for unrelated symptoms reported “moderate fatty change in the liver”. She is asymptomatic. BMI 34 kg/m², BP 138/86, HbA1c 44 mmol/mol, ALT 62 U/L (NR < 35), AST 38 U/L, ALP 96, GGT 64, bilirubin 12, platelets 240. She is teetotal and on no medications. Lipid profile: total cholesterol 5.6, HDL 1.0, LDL 3.6, triglycerides 2.0 mmol/L. What is the next most appropriate test to stratify her liver-related risk?
Correct answer: C. NICE NG49, BSG and EASL pathways align: FIB-4 is the universal non-invasive first test for any patient with steatosis on imaging plus a cardiometabolic risk factor. FIB-4 (calculated from age, AST, ALT, platelets) < 1.30 reassures; 1.30–2.67 triggers second-line elastography or ELF; > 2.67 prompts hepatology referral. Liver biopsy (A) is now reserved for diagnostic uncertainty after non-invasive work-up. Viral hepatitis serology (B) is reasonable but does not stratify fibrosis risk. Watchful waiting (D) misses fibrosis progression which can occur with normal ALT. UDCA (E) has no role in MASLD/MASH. The principal modifiable lever for her is weight reduction — lifestyle plus, given BMI 34 and prediabetes, considering a GLP-1 RA via NHS weight-management services where eligible.
Where the standard DCRM ladder requires deliberate adaptation
The DCRM 2.0 ladder is built around the average adult with multimorbidity. Four populations require explicit deviation: women (systemically under-treated for cardiovascular risk), pregnancy and preconception, frail older adults, and advanced CKD. Cancer survivorship is increasingly a fifth.
Women & the cardiometabolic care gap
Women remain less likely than men to be prescribed statin, ACE inhibitor or SGLT2 inhibitor at every level of risk (BHF / Heart UK 2024 audit). Perimenopausal cardiometabolic shift — visceral adiposity, ApoB rise, insulin resistance — is under-recognised. Lp(a) screening and ApoB measurement are particularly under-utilised in women. The 2023 ESC guideline on women’s CV disease and BMS 2022 guidance advocate explicit pathway parity.
Pregnancy & preconception in T2DM
Stop SGLT2 inhibitors, GLP-1 receptor agonists, tirzepatide, statins, ACE inhibitors and ARBs pre-conception (NICE NG3 / NG28). Switch to insulin or metformin; target HbA1c ≤ 48 mmol/mol if achievable safely. Pre-existing nephropathy and retinopathy can worsen in pregnancy. Refer to combined obstetric-diabetic clinic at diagnosis of pregnancy or before conception planning. Restart cardiometabolic agents postpartum based on lactation status.
Frail older adults
Use the Clinical Frailty Scale; frailty score ≥ 6 should drive deliberate de-escalation. Loosen HbA1c target to ≤ 64 mmol/mol; deprescribe sulfonylureas; review polypharmacy quarterly with explicit reference to anticholinergic burden, bleeding risk, and nutrition. SGLT2 inhibitor caution if BMI < 25 or risk of dehydration. Statins generally retained for secondary prevention if life expectancy > 1 year; primary prevention review individualised.
Advanced CKD (G4–G5)
SGLT2 inhibitors licensed down to eGFR 20 mL/min/1.73 m² (KDIGO 2024); continue once initiated until dialysis. Stop metformin at eGFR < 30. Reduce ACE inhibitor / ARB dose; tolerate creatinine rise up to 30%. Avoid finerenone if eGFR < 25 or K⁺ > 4.8. Insulin remains the safest glucose-lowering agent in advanced CKD; sulfonylurea risk of hypoglycaemia is high. Statins retain mortality benefit but only if not on dialysis (4D, AURORA trials negative).
Cancer survivorship — the emerging fifth special population. Survivors of breast, prostate, haematological and gastrointestinal malignancies have a higher cardiovascular event rate than matched non-cancer controls. Cardiotoxic chemotherapy (anthracyclines, trastuzumab) and androgen-deprivation therapy add cardiometabolic burden. The 2022 ESC Cardio-Oncology guideline endorses statin and BP control as standard, and screening for cardiomyopathy and arrhythmia. Integrate the Macmillan / NHS England cancer survivorship pathway into your DCRM clinic plan.
What is happening in the future? — the 2026–2030 DCRM pipeline
The pace of cardiometabolic drug development between 2024 and 2026 has been the fastest in any decade since the discovery of statins. Five drug classes are in late phase 3 with anticipated UK / EMA filings or approvals before 2028; a sixth (oral Lp(a) inhibition) is in mid-phase 3 with phase 2 read-outs already published. This section summarises the agents most likely to change UK primary-care DCRM practice within the lifetime of this PGCert cohort, with expert opinion to anchor each.
Pipeline at a glance
| Agent (INN) | Class · indication · key trial / readout | Anticipated UK arrival |
|---|---|---|
| Retatrutide | Triple GIP / GLP-1 / glucagon receptor agonist · obesity, T2DM, MASLD · TRIUMPH-1, -2, -3, -4 (2025–2026) | 2027–2028 (post-EMA) |
| Obicetrapib | Oral CETP inhibitor · ASCVD / FH lipid-lowering · BROADWAY (NEJM 2025), TANDEM, BROOKLYN | 2026–2027 (EMA review active) |
| Enlicitide (MK-0616) | Oral macrocyclic peptide PCSK9 inhibitor · LDL-C lowering · CORALreef Lipids, AddOn (2025); CORALreef Outcomes (2027) | 2027–2028 |
| Pelacarsen | Antisense oligonucleotide vs apo(a) · monthly SC · Lp(a) elevation in ASCVD · Lp(a)HORIZON (May 2025 readout) | 2026–2027 if HORIZON positive |
| Olpasiran | siRNA vs LPA mRNA · 12-weekly SC · Lp(a) elevation in ASCVD · OCEAN(a)-Outcomes (Dec 2026) | 2027–2028 |
| Lepodisiran | siRNA vs LPA mRNA · 6-monthly SC · Lp(a) elevation · ALPACA (phase 2, ACC.25); ACCLAIM-Lp(a) (phase 3, n≈12,500) | 2028–2029 |
| Muvalaplin | Oral small-molecule apo(a)-apoB binding inhibitor · Lp(a) elevation · KRAKEN (phase 2); MOVE-Lp(a) (phase 3, n≈10,450, 2031 completion) | 2030+ |
| CagriSema (cagrilintide + semaglutide) | GLP-1 + amylin combination · weekly SC · obesity, T2DM · REDEFINE-1 (NEJM 2025) — 22.7% weight loss at 68 weeks; FDA filing 2026 | 2027 |
| Baxdrostat | Aldosterone synthase inhibitor (CYP11B2) · oral · resistant hypertension · BaxHTN (NEJM ESC 2025); Bax24 phase 3 | 2026–2027 (FDA priority review accepted) |
| Lorundrostat | Aldosterone synthase inhibitor · oral · resistant hypertension · Launch-HTN phase 3 | 2027 |
| Low-dose colchicine 0.5 mg (Lodoco) | Anti-inflammatory · secondary prevention in stable CAD · LoDoCo2, COLCOT | UK access via NICE evaluation 2025–2026 |
| Resmetirom | Thyroid hormone receptor-β agonist · MASH F2-F3 · MAESTRO-NASH (NEJM 2024) | UK 2026–2027 specialist hepatology |
| Bimagrumab | Activin / myostatin pathway antagonist · muscle preservation in obesity pharmacotherapy · BELIEVE (phase 2b) | 2028+ |
| Ziltivekimab | Anti-IL-6 monoclonal antibody · residual inflammatory risk · ZEUS, ARTEMIS, COMBINE-2 (phase 3) | 2027–2028 |
The six classes most likely to reshape UK primary-care DCRM practice
Retatrutide
GIP / GLP-1 / glucagon triple agonist. TRIUMPH-4 (2025) demonstrated 28.7% mean weight loss at 68 weeks at 12 mg, with a 26.6% placebo-adjusted reduction. Improvements in CV risk markers, BP, knee osteoarthritis pain, and hepatic steatosis. Watch the dysesthesia signal at 12 mg (8.8–20.9%). Q4 2026 NDA filing anticipated.
Obicetrapib
Oral, low-dose, daily. BROADWAY (NEJM 2025; n > 2,500) showed 29.9% LDL-C reduction in patients on max-tolerated lipid therapy with HeFH or ASCVD; pooled phase 3 Lp(a) reduction ~45% in patients with baseline 50–150 nmol/L; 21% MACE reduction signal (HR 0.79, 95% CI 0.54–1.15). EMA review active; cognitive sub-analysis ongoing.
Enlicitide (MK-0616)
First oral PCSK9 inhibitor. CORALreef Lipids (2025) — 55.8% LDL-C reduction vs placebo at 24 weeks; near-equivalent to alirocumab and evolocumab on LDL-C, non-HDL-C, ApoB and Lp(a). CORALreef AddOn — superior to bempedoic acid, ezetimibe, and combination at 56 days. CORALreef Outcomes (n > 14,500) reads out 2027.
Pelacarsen · Olpasiran · Lepodisiran · Muvalaplin
Four mechanisms: antisense oligonucleotide (pelacarsen, monthly SC), siRNA (olpasiran 12-weekly, lepodisiran 6-monthly), and oral small-molecule apo(a)-apoB binding inhibitor (muvalaplin). Phase 2 reductions: pelacarsen ~80%; olpasiran ~94%; lepodisiran ~94% at 360 days from a single dose; muvalaplin ~86%. Outcome trials (Lp(a)HORIZON, OCEAN(a), ACCLAIM, MOVE-Lp(a)) read out 2025–2031.
CagriSema
Once-weekly fixed combination of cagrilintide (long-acting amylin analogue) and semaglutide. REDEFINE-1 (NEJM 2025; n > 3,400) showed 22.7% mean weight loss at 68 weeks; 60% achieved ≥ 20% weight loss; 23% achieved ≥ 30%. First once-weekly GLP-1 + amylin co-formulation. FDA filing late 2026; UK route under TA evaluation.
Baxdrostat · Lorundrostat
Selective CYP11B2 inhibitors — block aldosterone synthesis without affecting cortisol. BaxHTN (ESC 2025, NEJM): 9.8 mmHg placebo-adjusted SBP reduction in resistant hypertension at 12 weeks. Bax24 confirmed 13.9 mmHg ambulatory SBP reduction. FDA priority review accepted 2025. Likely first-in-class arrival in resistant hypertension within two years.
Expert voices — the cardiometabolic community on what comes next
The quotations below are kept under fifteen words verbatim per source for academic-fair-use compliance; longer commentary is paraphrased and synthesised.
On bempedoic acid & statin intolerance
Nissen, presenting CLEAR Outcomes at ACC 2023, framed bempedoic acid as “an effective approach to reduce major cardiovascular events” in genuine statin-intolerant patients. The PGCert reading: bempedoic acid is now the first non-statin oral with hard MACE outcome data, and finally retires the “nothing else works” clinical narrative.
On Lp(a) and risk re-classification
Ballantyne’s 2024 multi-ethnic cohort confirmed that Lp(a) at the 90th percentile carries an adjusted HR of 1.46 for ASCVD events, persisting “even in the presence of at-target” LDL-C. The PGCert reading: Lp(a) is the strongest single inherited dyslipidaemia and the population-level question is no longer “should we measure?” but “how do we treat?”
On SGLT2i + GLP-1 RA combination
Kosiborod’s body of work — STEP-HFpEF, FLOW, the HF-trial portfolio — has formalised the combined SGLT2i + GLP-1 RA prescription as “one of the most important advances” in cardiometabolic medicine. The PGCert reading: the two classes are additive, not redundant; co-prescription is the contemporary HFpEF + T2DM + obesity standard.
On the DCRM 2.0 vision
Handelsman, lead author of DCRM 2.0, frames the field as “a holistic approach to prevention and treatment” that transcends single-specialty silos. The PGCert reading: 22 multispecialty recommendations, two summary medication slides, and an explicit international (US + Europe + Canada) authorship reset the discipline as global rather than US-centric.
On CKM staging & PREVENT
Khan led the AHA PREVENT equations (Circulation 2024), which incorporate eGFR and UACR into a single CV risk calculator. The PGCert reading: CKM staging plus PREVENT is the first risk framework that prices kidney injury into cardiovascular risk at the moment of GP presentation. NICE NG238 will likely follow this lead at its next refresh.
On inclisiran and population lipid lowering
Ray, principal investigator on the ORION inclisiran programme, has framed twice-yearly siRNA delivery as the lever that “democratises” lipid lowering in primary care. The PGCert reading: ORION-4 long-term outcome data (2026–27) will determine whether inclisiran moves from third-line to second-line UK practice.
What to watch out for — the 2026–2028 readout calendar
The PGCert framing of the future. If the 2010s were the SGLT2i decade and the 2020s the GLP-1 decade, the 2026–2030 window will be defined by (a) Lp(a) becoming a treatable risk factor for the first time, (b) oral PCSK9 inhibition delivered in primary care, (c) once-weekly GLP-1 + amylin / triple-agonist obesity care displacing bariatric-surgery referral pathways, and (d) inflammation moving from biomarker to actively-drugged target. Plan your DCRM clinic capacity, your formularies, and your CPD around this calendar.
Professor-level multimorbidity — the patients referred to a DCRM clinic, not a single specialist
The three cases below sit deliberately above MRCGP-AKT difficulty. Each requires synthesis across at least three of the four DCRM microcredential domains and at least two guideline frameworks. Work through each case staged decision-by-staged decision; reveal the model answers only after committing to your own response. The model answers are written at consultant / senior GPwER level and cite the specific guideline by name and section.
38-year-old woman, 18-month T2DM, planning first pregnancy
A 38-year-old NHS administrator with a 6-year history of T2DM is referred from your DCRM clinic by her named GP for a preconception review. Her HbA1c is 71 mmol/mol on metformin 1 g twice daily, dapagliflozin 10 mg, semaglutide 1 mg weekly, gliclazide 80 mg twice daily, ramipril 10 mg, indapamide 2.5 mg, atorvastatin 80 mg and ezetimibe 10 mg. Latest blood pressure 138/86; BMI 32 kg/m²; eGFR 38 mL/min/1.73 m² (down from 52 a year ago); UACR 78 mg/mmol; serum K⁺ 4.9 mmol/L. She had laser-treated proliferative retinopathy two years ago and reports no current retinal disease. She would like to conceive within twelve months.
Q1 · Which of her current medications must stop pre-conception, and which continue?
Stop pre-conception: dapagliflozin (NICE NG28; teratogenicity signal in animal studies and limited human data); semaglutide (NICE TA875 contraindicated in pregnancy and recommends ≥ 2 months washout pre-conception); atorvastatin (FDA category X / NICE NG238 — stop pre-conception, restart postpartum if not breastfeeding); ezetimibe (limited safety data; stop in line with statin); ramipril and any other ACE inhibitor or ARB (associated with foetal renal dysplasia, oligohydramnios; switch pre-conception). Indapamide is generally avoided pre-conception due to volume depletion concerns affecting placental perfusion.
Continue or switch to: metformin (NICE NG3 endorses) at her current eGFR — but at eGFR 38 the dose should be halved to 500 mg twice daily and reviewed; insulin (now likely required given HbA1c 71); labetalol or methyldopa or modified-release nifedipine for blood pressure (NICE NG133 hypertension in pregnancy); aspirin 75–150 mg from 12 weeks for pre-eclampsia prevention if pregnant given her CKD and prior CV risk profile (NICE NG133); folic acid 5 mg pre-conception (T2DM and BMI > 30 indication, NICE NG3). Gliclazide should also be stopped before pregnancy and replaced with insulin given HbA1c 71 and fertility-planning timeline.
Anchor. NICE NG3 (Diabetes in pregnancy, 2020), NICE NG28, NICE NG133, MHRA SGLT2i pregnancy advisory.
Q2 · What HbA1c target and what insulin strategy do you recommend pre-conception, and why?
Target. NICE NG3 sets pre-conception HbA1c target at < 48 mmol/mol if achievable safely without disabling hypoglycaemia, with a strong recommendation to defer pregnancy if HbA1c is ≥ 86 mmol/mol. At 71 mmol/mol, conception should be deferred until target is achieved.
Insulin strategy. Given the loss of dapagliflozin and semaglutide and the renal-related risk of sulfonylurea-induced hypoglycaemia at eGFR 38, multiple-daily-injection basal-bolus insulin is the contemporary standard, with strong consideration of insulin pump and continuous glucose monitoring (NICE TA943 covers HCL pump for T1DM but the spirit of CGM use in T2DM at this risk threshold is endorsed by ADA 2026 and DCRM 2.0). She qualifies for funded CGM access via NHS England (T2DM on multiple insulin doses, recurrent severe hypoglycaemia, or hypoglycaemia unawareness — meet the third criterion if hypoglycaemia develops on initiation).
Retinopathy caveat. Rapid HbA1c improvement worsens proliferative retinopathy. Coordinate with retinal specialist; titrate over weeks to months rather than days to weeks; arrange retinal screen pre-conception, at first trimester, and 28 weeks if pregnant.
Anchor. NICE NG3; ADA Standards of Care 2026 §15; DCRM 2.0 Recommendation 12 (Antihyperglycaemic therapy in T2D) plus Hypoglycaemia §13.
Q3 · Her eGFR has fallen from 52 to 38 in 12 months. What is the cardiorenal management plan now, and what triggers nephrology referral?
Trajectory analysis. A fall from eGFR 52 to 38 in 12 months represents a sustained ≥ 25% decrease — this is a NICE NG203 indication for nephrology review and a KDIGO 2024 indication for accelerated multidisciplinary input. Combined with UACR 78 mg/mmol (A3) she sits in the “very-high-risk CKD” box of the heat map.
Cardiorenal plan once dapagliflozin and ramipril are stopped pre-conception. She loses both her main renoprotective agents. The clinical implication is that pregnancy at her current renal status carries significantly elevated risk of accelerated decline, pre-eclampsia, foetal growth restriction and preterm delivery. The plan is therefore (a) joint nephrology-obstetric-diabetes clinic referral; (b) urgent renal ultrasound to exclude obstructive cause; (c) close maternal monitoring with 4-weekly U&Es, ACR, BP and proteinuria during pregnancy; (d) explicit informed counselling on the maternal renal trajectory risk; (e) postpartum reinstitution of SGLT2i, ACE inhibitor, statin promptly after delivery if not breastfeeding.
Anchor. NICE NG203 (CKD assessment & management), KDIGO 2024 §3.1 (Risk classification), NICE NG3 §1.3 (Pregnancy in T2DM), DCRM 2.0 Recommendation 19 (CKD prevention & management).
67-year-old man, six months post-NSTEMI, persistent residual lipid risk
A 67-year-old retired schoolteacher had a non-ST-elevation MI six months ago. He is on aspirin, clopidogrel, ramipril 10 mg, bisoprolol 5 mg and dapagliflozin 10 mg. He has tried atorvastatin 80, rosuvastatin 40, simvastatin 40, pravastatin 40 and pitavastatin 4 mg sequentially — each producing reproducible bilateral thigh myalgia confirmed on three separate N-of-1 blinded re-challenges (the SAMSON-style protocol arranged via your DCRM clinic). Latest bloods on no statin: LDL-C 4.6 mmol/L, total cholesterol 5.9, HDL 1.1, TG 1.4, ApoB 1.42, Lp(a) 280 nmol/L, hsCRP 3.6 mg/L, eGFR 38, UACR 4 mg/mmol, K⁺ 4.5, ALT 28. Father had MI at 49 and died at 55; brother had MI at 53 — Simon-Broome “possible” FH on history alone.
Q1 · How do you build a non-statin lipid plan to ESC/EAS 2025 extreme-risk targets?
Target. Established ASCVD with a recurrent-risk profile (post-MI, FH-clinical, Lp(a) ≥ 250, CKD) places him in the ESC/EAS 2025 extreme risk category — LDL-C < 1.0 mmol/L; ApoB < 0.65 g/L. He is at LDL 4.6 — a gap of ≥ 78%.
Plan. Given true confirmed statin intolerance after five-statin re-challenge, the contemporary non-statin ladder is: ezetimibe 10 mg + bempedoic acid 180 mg (Nustendi single-pill, NICE TA694) — combined ~38–40% LDL-C reduction. Add a PCSK9 inhibitor — alirocumab 150 mg fortnightly, evolocumab 140 mg fortnightly, or inclisiran 284 mg (NICE TA733) twice yearly after loading, depending on patient preference and local commissioning. Combination expected reduction ~70–75%. Reassess at 12 weeks. Consider adding icosapent ethyl 2 g twice daily (NICE TA805) if TG remains ≥ 1.7 on secondary-prevention statin — not directly applicable here since statins are unavailable, but worth retaining if any statin tolerance develops.
Anchor. ESC/EAS 2025 dyslipidaemia focused update; DCRM 2.0 Recommendation 9; NICE NG238 §1.6 (residual risk in established CVD); NICE TAs 393 / 394 / 694 / 733 / 805.
Q2 · His Lp(a) is 280 nmol/L. What is the current treatment-specific approach, and what are his future options?
Current. No UK-licensed Lp(a)-specific therapy exists in 2026. The clinical implication of an Lp(a) of 280 nmol/L (ASCVD relative risk roughly equivalent to LDL-C 4 mmol/L untreated) is to (a) push every other lever harder — LDL-C target < 1.0 mmol/L per ESC/EAS 2025 extreme-risk floor; BP < 130/80; weight optimisation; smoking cessation; (b) screen first-degree relatives — Heart UK and ESC/EAS 2025 endorse cascade testing in the context of premature familial CV disease; (c) optimise antiplatelet regimen (he is already on aspirin + clopidogrel post-NSTEMI); (d) consider apheresis referral via specialist lipid clinic if recurrent events on optimal therapy — currently rationed in the UK to homozygous FH and severe FH refractory cases.
Future. He is exactly the patient who should be referenced for clinical trial consideration. Lp(a)HORIZON pelacarsen reads out 2026; OCEAN(a)-Outcomes olpasiran reads out December 2026; ACCLAIM-Lp(a) lepodisiran is recruiting; KRAKEN / MOVE-Lp(a) muvalaplin (oral) is recruiting. Document Lp(a) prominently in his records — flag for first-line consideration once any of these agents reach NICE.
Anchor. ESC/EAS 2025 (Lp(a) chapter); NLA 2024 focused update; Ballantyne et al, JACC 2024; Heart UK Lp(a) consensus; Lp(a)HORIZON design paper, Tsimikas et al, AHJ 2024.
Q3 · How do you handle his combined cardiorenal protection with eGFR 38 and a high inflammation signature (hsCRP 3.6 mg/L)?
Cardiorenal. He is already on dapagliflozin (NICE TA775 in CKD); continue down to eGFR 20 per KDIGO 2024. Continue ramipril at maximum tolerated; if K⁺ rises consider adding patiromer or sodium zirconium cyclosilicate to allow RAAS continuation. Add finerenone (NICE TA877) if UACR ≥ 3 mg/mmol — his is 4 mg/mmol so he qualifies; baseline K⁺ 4.5 is acceptable; recheck K⁺ at 4 weeks then quarterly. Avoid spironolactone (steroidal MRA) given his CKD G3b status and risk of hyperkalaemia.
Inflammation. hsCRP 3.6 mg/L on no statin — the residual inflammatory risk channel is open. Once lipid lowering is in place, consider low-dose colchicine 0.5 mg daily per LoDoCo2 / COLCOT (32% MACE reduction in stable CAD with persistent inflammation), pending NICE TA outcome. Watch ziltivekimab (anti-IL-6) phase 3 (ZEUS / ARTEMIS) — likely 2027–28 arrival.
Anchor. KDIGO 2024 §4 and §5 (cardiorenal management); NICE NG203; NICE TA877; LoDoCo2, NEJM 2020; DCRM 2.0 Recommendation 11 (Inflammation) and Recommendation 17 (ASCVD).
75-year-old woman, recurrent decompensations, considering deprescribing and rebuilding
A 75-year-old retired headteacher with Clinical Frailty Score 6 attends the DCRM clinic after two recent hospital admissions for HFpEF decompensation. T2DM 22-year duration; she is on insulin glargine 30 units nocte, gliclazide 160 mg twice daily, sitagliptin 100 mg daily, furosemide 80 mg daily, ramipril 5 mg daily, atorvastatin 40 mg daily, and aspirin 75 mg daily. BMI 39 kg/m²; HbA1c 78 mmol/mol; BP 142/68; eGFR 45; UACR 22 mg/mmol; K⁺ 4.6; NT-proBNP 1,820 ng/L; LVEF 56% on recent TTE; ALT 64; AST 42; platelets 220; FIB-4 calculated 2.84. She has reproducible falls (three in past year, no fracture) and reports two episodes of severe nocturnal hypoglycaemia in the last fortnight requiring family assistance.
Q1 · What is the deprescribing priority, and why is sequencing critical?
Priority order — stop these first. (1) Gliclazide — she has had two Level 3 (severe, requires assistance) hypoglycaemic events in a fortnight; sulfonylureas in CKD G3b with frailty should be discontinued (DCRM 2.0 Recommendation 13; NICE NG28 individualised target ≤ 64 mmol/mol). (2) Sitagliptin — CV-neutral and clinically redundant once sulfonylurea is stopped and an organ-protective agent is added. (3) Aspirin — primary prevention only; she has no history of MI or stroke; the 2026 ACC/AHA guideline and DCRM 2.0 Recommendation 14 recommend against routine primary-prevention aspirin in this risk-benefit profile.
Glycaemic relaxation. Move HbA1c target to ≤ 64 mmol/mol per NICE NG28 individualised target — frailty + recurrent severe hypoglycaemia + life-expectancy considerations all push the same way. Reduce insulin glargine by 20% on initiation of any new GLP-1 RA / SGLT2i to pre-empt hypoglycaemia.
Anchor. NICE NG28 §1.6.7; DCRM 2.0 §2.2.6 and §2.2.7; STOPP/START version 3 (2023) criteria for older adults; British Geriatrics Society guidance on frailty and diabetes.
Q2 · What does the rebuilt regimen look like — covering HFpEF, T2DM, CKD, MASLD and obesity?
Add. Empagliflozin 10 mg daily (NICE TA929 HFmrEF/HFpEF; TA989 CKD; NICE NG28 T2DM) — covers four spokes simultaneously. Finerenone 10 mg daily (NICE TA877; UACR 22 mg/mmol; eGFR 45; K⁺ 4.6 — qualifies); recheck K⁺ at 4 weeks. Semaglutide 1 mg weekly subcutaneous (NICE NG28 in T2DM; STEP-HFpEF supports use in HFpEF + obesity at the 2.4 mg dose; FLOW supports renal benefit) — but pre-emptively reduce her basal insulin by 20% and stop gliclazide first.
Continue or adjust. Ramipril — increase to 10 mg if BP and K⁺ permit, after finerenone settles. Furosemide — titrate to symptoms, not absolute dose; aim minimum effective. Atorvastatin — continue; secondary-prevention indication remains given her DCRM risk. Stop aspirin.
MASLD. FIB-4 2.84 (> 2.67) triggers hepatology referral per NICE NG49 / EASL; a 7–10% weight reduction on the GLP-1 RA at the higher 2.4 mg dose may itself reverse MASH. Avoid hepatotoxic agents.
Anchor. NICE NG28; NICE TAs 877, 929, 989; DCRM 2.0 Recommendations 12, 16, 18, 20; FINEARTS-HF / FLOW / STEP-HFpEF / EMPEROR-Preserved / DELIVER.
Q3 · How do you frame the prognostic conversation with this patient and her family?
Honest framing. She has stage 4 CKM syndrome (clinical CVD with multiple metabolic risk factors and CKD; AHA Presidential Advisory 2023). Median life expectancy from this stage at age 75 is well-modelled and is dominated by CV death and decompensated HF. Her frailty score, hypoglycaemia history, and fall risk push the conversation toward quality-of-life optimisation rather than aggressive risk-factor targeting.
Goal-setting. Use a structured shared decision-making tool — the TIME (Treatment Implications: Make Explicit) framework or the BGS frailty-and-diabetes resource. Specific targets: stop her falling, stop her hypoglycaemia, reduce her HF admissions, retain enough function to live independently. Less focus on absolute HbA1c, BP, LDL-C numbers; more on aligning her medication burden with what she values.
Family engagement. Document the conversation. Consider parallel completion of a ReSPECT form. Identify her named lasting power of attorney for health if she has one; if not, raise the conversation gently. The DCRM clinic visit is also the opportunity to raise advance care planning when the patient is well — not deferred to the next acute admission.
Anchor. AHA CKM Presidential Advisory 2023; British Geriatrics Society frailty guidance; NICE NG56 multimorbidity; ReSPECT framework; STOPP/START version 3.
Two items per pillar — alongside the four embedded in-section knowledge checks
Each item is written in clinical-vignette form with a single best answer and four defensible-but-wrong distractors, pitched at synoptic-PGCert level (above MRCGP-AKT). Click each summary to reveal the question, options, and the rationale with explicit guideline citation. The eight items below are in addition to the four embedded mini-SBAs at the end of each pillar section (Lipid, Diabetes, Cardiorenal, Obesity / MASLD) — twelve items in total across the module.
How to use this integrative check. Work through all eight items in one sitting before opening the rationales — this trains the synoptic-style synthesis the PGCert assessments require. Aim for ≥ 6 / 8 across the integrative check, plus ≥ 3 / 4 across the four embedded mini-SBAs. The full sample DCRM Synoptic Self-Assessment is the 20-item instrument designed for revision and self-assessment after the module.
Pillar 1 · Lipid management · SBAs 1–2
SBA 1 · Lipid · 71-year-old with confirmed statin intolerance and ASCVD
A 71-year-old woman with two prior ischaemic strokes is reviewed in your DCRM clinic. She has had reproducible bilateral thigh myalgia and a CK rise to 580 U/L on atorvastatin 20 mg, then on rosuvastatin 5 mg, then on simvastatin 10 mg, each with full symptom resolution on cessation. She tolerates ezetimibe 10 mg daily without issue. eGFR 62, ALT 22, K⁺ 4.4, BP 132/76. Latest non-fasting LDL-C 3.2 mmol/L on ezetimibe alone; Lp(a) 80 nmol/L; ApoB 1.10 g/L. She is on ramipril, indapamide, clopidogrel and dapagliflozin. What is the most appropriate next pharmacological step?
Correct answer: C. She has true statin intolerance after three N-of-1 challenges and is above her secondary-prevention LDL-C target (NICE NG238 < 2.0; ESC/EAS 2025 very-high risk < 1.4). Bempedoic acid (NICE TA694) is the next oral step — CLEAR Outcomes (Nissen, NEJM 2023; n = 13,970; HR 0.87) demonstrated 13% MACE reduction in statin-intolerant patients. Adding bempedoic acid to ezetimibe gives a further ~17–22% LDL-C reduction without skeletal-muscle effect (active only in the liver). Pitavastatin (A) re-challenge after three reproducible failures is unlikely to succeed. Inclisiran (B) is appropriate after maximal oral non-statin therapy still leaves LDL ≥ 2.6 mmol/L (NICE TA733). Icosapent ethyl (D) would only apply if TG ≥ 1.7 mmol/L. Evinacumab (E) is reserved for homozygous FH.
SBA 2 · Lipid · Post-PCI patient with persistent LDL above target on triple therapy
A 59-year-old man underwent two-vessel PCI 9 months ago. He is on aspirin, ticagrelor (continued for 12 months), atorvastatin 80 mg, ezetimibe 10 mg, ramipril 10 mg, bisoprolol 5 mg and dapagliflozin 10 mg for T2DM. He is fully adherent (verified by pharmacy refills and a structured interview). HbA1c 49 mmol/mol, eGFR 71, BP 124/74. Latest non-fasting LDL-C 2.4 mmol/L; non-HDL-C 3.1; ApoB 0.95 g/L; Lp(a) 120 nmol/L. He has tolerated atorvastatin without symptoms. Which is the most appropriate next step in lipid intensification?
Correct answer: E. He has established ASCVD with diabetes (very-high risk) and is above ESC/EAS 2025 LDL-C target of < 1.4 mmol/L despite max-tolerated statin plus ezetimibe. NICE TA393 (alirocumab) and TA394 (evolocumab) recommend PCSK9 monoclonal antibodies for adults with established CVD and persistent LDL-C ≥ 2.6 mmol/L despite max-tolerated statin and ezetimibe; NICE TA733 recommends inclisiran on the same indication with the additional advantage of twice-yearly subcutaneous administration. The Lp(a) of 120 nmol/L further supports intensification. Doubling atorvastatin (A) is not licensed and produces little additional LDL reduction. Bempedoic acid (B) is reserved for statin intolerance or as add-on if PCSK9 access is delayed. Icosapent ethyl (C) addresses TG, not LDL. Watchful waiting (D) ignores the residual risk.
Pillar 2 · Diabetes & cardiometabolic therapy · SBAs 3–4
SBA 3 · Diabetes · Patient on tirzepatide presenting with persistent abdominal pain
A 54-year-old woman with T2DM and obesity has been on tirzepatide 10 mg weekly for four months. She has lost 14% body weight, HbA1c 47 mmol/mol. She presents to your urgent appointment with three days of constant epigastric pain radiating to her back, worse on lying flat, with one episode of vomiting and reduced oral intake. She denies alcohol excess. Examination: tender epigastrium without peritonism; HR 96, BP 124/78, temperature 37.1°C, capillary glucose 8.4 mmol/L. What is the most appropriate immediate management?
Correct answer: B. Acute pancreatitis is a class-effect adverse event of GLP-1 and dual GIP/GLP-1 receptor agonists. The clinical pattern (constant epigastric pain radiating to the back, worse on lying flat, vomiting, days’ duration) requires immediate cessation of the suspected agent and same-day biochemistry plus imaging. NICE TA924 / TA1026 and the Mounjaro SmPC explicitly require discontinuation if pancreatitis is suspected; do not re-challenge if biochemically or radiologically confirmed. A delayed amylase/lipase by even 24 hours risks missing diagnosis. Continuing the agent (A, C, D) misses a potentially serious diagnosis. Symptomatic gallstones are also more common in this class — abdominal ultrasound covers both. Stopping dapagliflozin (E) does not address the diagnostic question.
SBA 4 · Diabetes · BMI 38, T2DM, choosing between semaglutide and tirzepatide
A 47-year-old man with T2DM (HbA1c 71 mmol/mol on metformin 1 g twice daily and dapagliflozin 10 mg) attends your clinic. BMI 38 kg/m²; BP 134/82; eGFR 86; UACR 1.4 mg/mmol. He has no history of MI, stroke, HF or pancreatitis. He drives professionally and prefers a once-weekly subcutaneous regimen. He has not previously had a GLP-1 receptor agonist. He has commercial insurance through his employer and access to either NHS- or private-prescribed therapy. Which option provides the greatest combined glycaemic and weight reduction at the licensed UK doses?
Correct answer: D. SURPASS-2 (NEJM 2021), SURMOUNT-1 (NEJM 2022) and SURPASS-CVOT (NEJM 2025) demonstrated that tirzepatide at the 10 mg and 15 mg weekly doses produces greater HbA1c reduction (~2.0–2.4%) and greater weight loss (~21% at 72 weeks in obesity, ~12% in T2DM at 40 weeks) than any UK-licensed GLP-1 RA monotherapy at maximally licensed doses. NICE TA924 (T2DM) and TA1026 (obesity) endorse tirzepatide. Liraglutide (A) and dulaglutide (B) are appropriate first-line GLP-1 RAs but produce smaller weight loss. Oral semaglutide (C) is licensed at 14 mg for T2DM but the weight-loss magnitude is modest at this dose; the 25 mg oral formulation (now licensed) is closer but still smaller than tirzepatide 15 mg. Insulin (E) addresses glycaemia but worsens weight in this BMI 38 patient. The selection should also account for cost, NHS/practice formulary, and patient preference; NICE prescribing-cost analysis of GLP-1 RAs is updated annually.
Pillar 3 · Cardiorenal axis · SBAs 5–6
SBA 5 · Cardiorenal · Non-diabetic CKD with albuminuria
A 63-year-old man without diabetes is reviewed in your DCRM clinic with eGFR 41 mL/min/1.73 m² (stable for 18 months) and UACR 38 mg/mmol on his last three samples. He is on ramipril 10 mg, amlodipine 5 mg and atorvastatin 40 mg. BP 128/76; HbA1c 38 mmol/mol; K⁺ 4.4. He has no history of CVD or HF. Which addition to his regimen is most appropriate, per NICE NG203 and KDIGO 2024?
Correct answer: A. NICE TA775 (dapagliflozin) and TA989 (empagliflozin) recommend SGLT2 inhibitors for adults with CKD eGFR 25–75 mL/min/1.73 m² and UACR ≥ 22.6 mg/mmol (or ≥ 22.6 mg/g) regardless of diabetes status. KDIGO 2024 endorses use down to eGFR 20. DAPA-CKD and EMPA-KIDNEY demonstrated reduced kidney composite outcome in patients with and without diabetes. Finerenone (B) is currently NICE-licensed only for T2DM-CKD (NICE TA877). Semaglutide (C) is not currently NICE-licensed for non-diabetic CKD though FLOW data may shape future guidance. Spironolactone (D) is not first-line in CKD G3 with K⁺ approaching the upper safe range. Watchful waiting (E) misses a TA-mandated indication.
SBA 6 · Cardiorenal · Adding finerenone to a patient already on spironolactone
A 64-year-old man with T2DM, HFrEF (LVEF 32%) and CKD (eGFR 44, UACR 24 mg/mmol) is on sacubitril-valsartan 49/51 mg twice daily, bisoprolol 5 mg, dapagliflozin 10 mg, spironolactone 25 mg, atorvastatin 80 mg and ezetimibe 10 mg. He is well-compensated. K⁺ 4.6, eGFR stable. He attends for medication review and asks about finerenone, having read about FINEARTS-HF. Which is the most appropriate response?
Correct answer: C. Finerenone (a non-steroidal MRA) and spironolactone (a steroidal MRA) act on the same receptor and must not be co-prescribed — both NICE TA877 and the BNF prohibit dual MRA. The decision is whether to switch from spironolactone to finerenone. In HFrEF, the existing evidence base for spironolactone is RALES (mortality benefit). Finerenone’s strongest HFmrEF/HFpEF data come from FINEARTS-HF. He is HFrEF, so spironolactone is the preferred MRA per NICE NG106 / ESC 2023 HF guideline; switching to finerenone is therefore not routine. Specialist HF review is appropriate before any switch. (A) Stopping dapagliflozin is wrong — quadruple therapy benefit in HFrEF demands its retention. (B) Co-prescription is contraindicated. (D) ARNI dose reduction is unnecessary and would lose mortality benefit. (E) Stopping bisoprolol is contraindicated in stable HFrEF.
Pillar 4 · Obesity, MASLD & inflammation · SBAs 7–8
SBA 7 · Obesity · Established CVD without diabetes — semaglutide eligibility
A 56-year-old man had a STEMI 12 months ago. He is on aspirin, ticagrelor (recently stopped at 12 months), atorvastatin 80 mg, ezetimibe 10 mg, ramipril 10 mg, bisoprolol 5 mg and dapagliflozin 10 mg (added for HFpEF post-MI). HbA1c 41 mmol/mol; BMI 34 kg/m²; LDL-C 1.4 on combination therapy; eGFR 78. He does not have diabetes. He asks whether the “weight-loss injection” he has heard about could help. What is the appropriate response, anchored to current NICE guidance and the SELECT trial?
Correct answer: D. NICE TA875 (March 2023) recommends semaglutide 2.4 mg subcutaneous weekly (Wegovy) for adults with BMI ≥ 35 (or ≥ 30 with risk factor) and at least one weight-related comorbidity, via NHS specialist weight-management services for two years. The SELECT trial (Lincoff, NEJM 2023; n = 17,604) demonstrated 20% MACE reduction with semaglutide 2.4 mg in adults with overweight/obesity and established CVD without diabetes — strengthening the cardiovascular case for this exact patient. Decline framings (A, B) are factually incorrect. Bariatric surgery (C) may still be appropriate but is not the first step. Off-label initiation in primary care (E) bypasses the TA875 specialist-service pathway.
SBA 8 · MASLD · Indeterminate FIB-4 in T2DM
A 52-year-old woman with T2DM (8-year duration, HbA1c 56 mmol/mol on metformin and dapagliflozin) attends for annual review. She is asymptomatic, BMI 31. Routine bloods show ALT 48 (NR < 35), AST 36, platelets 250, GGT 70, ALP 92, bilirubin 9. She is on no hepatotoxic medications and drinks < 6 units/week. Lipid profile, viral hepatitis serology and autoimmune screen are all negative. FIB-4 (calculated) = 1.62. What is the most appropriate next investigation?
Correct answer: B. The pathway is FIB-4 first; if < 1.30 reassure and recheck periodically; if 1.30–2.67 indeterminate proceed to second-line non-invasive (transient elastography by FibroScan giving a liver-stiffness measurement, or the ELF blood test); if > 2.67 refer to hepatology directly. NICE NG49, BSG and EASL 2024 align on this. Her FIB-4 of 1.62 is in the indeterminate range; B is the correct next step. Repeating FIB-4 (A) defers diagnosis. Liver biopsy (C) is reserved for diagnostic uncertainty after non-invasive work-up. UDCA (D) has no role in MASLD/MASH. Stopping dapagliflozin (E) is unwarranted — dapagliflozin has hepatic-fat-fraction reduction signal in T2DM-MASLD.
Self-marking. Eight items at AKT to PGCert challenge level. Distribution of correct answers: A = 1, B = 2, C = 2, D = 2, E = 1. Eight correct = exit competence at MRCGP-AKT level on this body of material; 6+ = strong; 4–5 = revisit the relevant pillar; < 4 = repeat the section before progressing to the four-microcredential PGCert. The full PGCert assessments include 60 SBAs across the four microcredentials plus an integrative case-based capstone.
MD Acumen Academy
This certifies that
Your name will appear here
has completed the introductory PGCert taster module
DCRM Foundations — Diabetes-Cardiorenal-Metabolic Medicine
Authored by Prof Rajesh Varma · MD Acumen Ltd · mdacumen.com
Curriculum-aligned with DCRM 2.0 (Handelsman et al, Metabolism 2024); NICE NG28 / NG203 / NG238 / NG49; KDIGO 2024; ESC/EAS 2025 dyslipidaemia focused update; AHA CKM Presidential Advisory 2023.
Reflective practice prompts
Before saving the certificate, spend five focused minutes on these prompts. Reflective practice is the part of CPD that changes practice — the patients you identify, the templates you change, the conversations you initiate over the next quarter.
Your personal reflection — for your CPD portfolio
Use the box below to record what you have learnt and how you will apply it. Saved locally in your browser; included on the printable certificate above when you click Print / Save as PDF, giving you a single portfolio document combining your name, date, completion confirmation, and reflection.
Saved automatically as you type. The reflection appears on the printable certificate when you click Print / Save as PDF.
Continue your CPD journey
Multiple onward routes — explore the full PGCert programme, browse another sample module, or return to the Academy.
Key sources & further reading
All clinical content in this module is drawn from independent peer-reviewed and recognised guideline-issuing bodies. Where multiple licensed agents within a class are discussed, they are presented even-handedly per their NICE technology appraisals. The 12-link reference grid below is curated for clinical utility; an expanded source list follows beneath.
Expanded source list
Handelsman Y, Anderson JE, Bakris GL et al. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Metabolism 2024;159:155931. · Ndumele CE, Rangaswami J, Chow SL et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation 2023;148:1606–1635. · 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis 2025. · KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD. Kidney Int Suppl 2024. · Nissen SE, Lincoff AM, Brennan D et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients (CLEAR Outcomes). N Engl J Med 2023;388:1353–1364. · Solomon SD, McMurray JJV, Vaduganathan M et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction (FINEARTS-HF). N Engl J Med 2024;391:1475–1485. · Lincoff AM, Brown-Frandsen K, Colhoun HM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med 2023;389:2221–2232. · Perkovic V, Tuttle KR, Rossing P et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med 2024;391:109–121. · Nicholls SJ, Nissen SE, Fleming C et al. Safety and efficacy of obicetrapib in patients at high cardiovascular risk (BROADWAY). N Engl J Med 2025. · Tsimikas S et al. Lp(a)HORIZON pelacarsen design. Am Heart J 2024. · Ballantyne CM, Pirruccello JP, Berman AN et al. Lipoprotein(a) and long-term cardiovascular risk in a multi-ethnic pooled prospective cohort. JACC 2024. · Khan SS, Coresh J, Pencina MJ et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease (PREVENT). Circulation 2024. · Aronne LJ, Sattar N, Horn DB et al. Cagrilintide–semaglutide in adults with overweight or obesity (REDEFINE-1). N Engl J Med 2025. · Lilly press release — TRIUMPH-4 retatrutide topline (2025). · Merck press release — CORALreef Lipids enlicitide phase 3 (2025). · AstraZeneca press release — BaxHTN baxdrostat phase 3 (ESC 2025). · Heart UK Lp(a) consensus statement 2024. · NLA focused update on Lp(a) 2024.
Educational disclaimer. Intended for the continuing professional development of qualified UK healthcare professionals at postgraduate level. Does not replace clinical judgement, local prescribing formularies, or specialist advice. Drug doses and recommendations reflect UK practice at the time of authoring; readers must check the current British National Formulary and the relevant NICE guidance before prescribing. Emerging-therapy content reflects publicly disclosed phase 2 and phase 3 trial data and announcements available to May 2026; regulatory status and licensing may change after the date of authoring.
© 2026 MD Acumen Ltd. · Registered in England and Wales · 16538952 · Legal & Regulatory Information · enquiry@mdacumen.com